Bone Marrow Aspirate Concentrate (BMAC) Treatment for Knee Osteoarthritis

Trial details

Who runs it

CELL Technologies Inc.

Trial code

NCT06216028

Record updated

24 May 2024

Original description

The purpose of the ACCELERATE3 trial is to assess the efficacy of a single intra-articular (IA) injection of autologous BMAC, in one or both knees, compared to a single IA injection of Standard of Care (SOC) in patients with mild to severe knee OA.Read full original descriptionShow less

Bone Marrow Aspirate ConCentrate for the Treatment of knEe Osteoarthritis: A Phase III, muLti-centER, Pan-cAnadian, prospecTivE Trial

The purpose of the ACCELERATE3 trial is to assess the efficacy of a single intra-articular (IA) injection of autologous BMAC, in one or both knees, compared to a single IA injection of Standard of Care (SOC) in patients with mild to severe knee OA.

Inclusion: Male or female subjects ≥ 40 years old; The subject must have a clinical diagnosis of osteoarthritis (OA) of one or both knees supported by radiological evidence (Kellgren Lawrence Grade II-IV) which is assessed locally (x-rays within the past 6 months of screening are acceptable); Subjects whose knee pain persists for at least 12 weeks (about 3 months) prior to screening and does not improve symptoms with pain medications and non-operative treatment options; Subject who has knee pain ≥ 40 mm out of 100 mm on single question VAS (Visual Analog Scale) at Screening (Visit 1) and prior to Randomization (Visit 2); Note: Subject should meet this criterion for left and right knee separately to be eligible for bilateral study treatment; The subject is willing to provide written informed consent to participate in the study after reading the informed consent form and the information provided and has had the opportunity to discuss the study with the investigator or designee; The subject is able to communicate satisfactorily with the investigator and to participate in, and comply with, the requirements of the study; The subject is able to understand the nature of the study and any potential hazards associated with participating in it; Negative pregnancy test for female subjects of childbearing potential.

Exclusion: Subjects who have knee replacement surgery planned within 6 months of enrollment; Prior Partial Joint Replacement (PJR) or Total Joint Replacement (TJR) of one or both knees; Knee surgery in the previous 6 months prior to enrollment; Concomitant inflammatory disease or other condition affecting the joints (e.g., rheumatoid arthritis, septic arthritis, inflammatory joint disease, metabolic bone disease, psoriasis, gout, microcrystalline arthropathies/chondrocalcinosis, Paget's disease); A diagnosis of any form of cancer in the previous 6 months; Actively treated with oral anticoagulants or heparin therapy (treatment such as low dose Aspirin and Plavix are allowed); Participation in another clinical trial or treatment with another investigational product within 30 days prior to inclusion in the study; Congenital or acquired diseases leading to significant knee deformities that may interfere with cell application or the interpretation of results; Signs of active uncontrolled infection or known history of HIV, hepatitis, or syphilis; Other conditions that may, according to medical criteria, discourage participation or impact outcome evaluation in the study; Subjects with a BMI ≥ 30kg/m2; Instances of widespread pain or any pain that could interfere with the assessment of index knee pain (e.g. pain in any other part of the lower extremities, pain radiating to the knee).

ClinicalTrials.gov NCT06216028